GlobeNewswire
-
Picard Medical/ SynCardia Highlights Successful Bridge-to-Transplant Case at UCSF Health Using the SynCardia Total Artificial Heart
12/02/2026 -
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
12/02/2026 -
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
12/02/2026 -
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
12/02/2026 -
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
12/02/2026 -
Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026
12/02/2026 -
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301
12/02/2026 -
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
12/02/2026 -
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
12/02/2026 -
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
12/02/2026 -
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
12/02/2026 -
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG
12/02/2026 -
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
12/02/2026 -
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
12/02/2026 -
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
12/02/2026 -
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi
12/02/2026 -
Nicox confirme son éligibilité au PEA-PME
12/02/2026 -
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
12/02/2026 -
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
12/02/2026
Pages